Pulmonary hypertension caused by congestive heart failure is ameliorated by long-term application of an endothelin receptor antagonist Increased expression of endothelin-1 messenger ribonucleic acid and endothelin-1-like immunoreactivity in the lung in congestive heart failure in rats
- 15 November 1996
- journal article
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 28 (6), 1580-1588
- https://doi.org/10.1016/s0735-1097(96)00336-1
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Elevated levels of plasma endothelin-1 in young patients with pulmonary hypertension caused by congenital heart disease are decreased after successful surgical repairThe Journal of Thoracic and Cardiovascular Surgery, 1995
- Pressure Enhances Endothelin-1 Release From Cultured Human Endothelial CellsHypertension, 1995
- Absence of pulmonary endothelin gradient in patients with Normal or elevated circulating endothelinThe American Journal of Cardiology, 1994
- Is endothelin-induced vasoconstriction mediated only by ETA receptors in humans?Trends in Pharmacological Sciences, 1994
- Plasma endothelin and pulmonary pressures in patients with congestive heart failureAmerican Heart Journal, 1993
- Antihypertensive effect of a newly synthesized endothelin antagonist, BQ-123, in a genetic hypertensive modelLife Sciences, 1993
- Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptorLife Sciences, 1992
- An overview of contemporary etiologies of congestive heart failureAmerican Heart Journal, 1991
- cDNA cloning, sequence analysis and tissue distribution of rat preproendothelin-1 mRNABiochemical and Biophysical Research Communications, 1991
- Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril.Circulation, 1985